188
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Analysis of Drug-Resistant Bacteria from Different Regions of Anhui in 2021

ORCID Icon, , , , , , , , & show all
Pages 7537-7553 | Received 17 Oct 2022, Accepted 14 Dec 2022, Published online: 21 Dec 2022

References

  • McEwen SA, Collignon PJ. Antimicrobial resistance: a one health perspective. Microbiol Spectr. 2018;6(2). doi:10.1128/microbiolspec.ARBA-0009-2017
  • Ferri M, Ranucci E, Romagnoli P, Giaccone V. Antimicrobial resistance: a global emerging threat to public health systems. Crit Rev Food Sci Nutr. 2017;57(13):2857–2876. doi:10.1080/10408398.2015.1077192
  • Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, M100. 31st ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2021.
  • Hu F, Guo Y, Yang Y, et al.; China Antimicrobial Surveillance Network (CHINET) Study Group. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38(12):2275–2281. doi:10.1007/s10096-019-03673-1
  • Shariati A, Dadashi M, Moghadam MT, van Belkum A, Yaslianifard S, Darban-Sarokhalil D. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis. Sci Rep. 2020;10(1):12689. doi:10.1038/s41598-020-69058-z
  • Zhang DX, Li Y, Yang XQ, et al. In vitro antibiotic susceptibility, virulence genes distribution and biofilm production of Staphylococcus aureus isolates from bovine mastitis in the Liaoning Province of China. Infect Drug Resist. 2020;11(13):1365–1375. doi:10.2147/IDR.S247765
  • Liang B, Mai J, Liu Y, et al. Prevalence and characterization of Staphylococcus aureus isolated from women and children in Guangzhou, China. Front Microbiol. 2018;16(9):2790. doi:10.3389/fmicb.2018.02790
  • Cheah AL, Spelman T, Liew D, et al. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clin Microbiol Infect. 2013;19(4):E181–E189. doi:10.1111/1469-0691.12132
  • Bender JK, Cattoir V, Hegstad K, et al. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: towards a common nomenclature. Drug Resist Updat. 2018;40:25–39. doi:10.1016/j.drup.2018.10.002
  • Asgin N, Otlu B. Antibiotic resistance and molecular epidemiology of vancomycin-resistant enterococci in a tertiary care hospital in Turkey. Infect Drug Resist. 2020;21(13):191–198. doi:10.2147/IDR.S191881
  • Wei Y, Zhang H, Fu M, Ma R, Li R, Kong L. Plasma and intrapulmonary pharmacokinetics, and dosage regimen optimization of linezolid for treatment of gram-positive cocci infections in patients with pulmonary infection after cerebral hemorrhage. Infect Drug Resist. 2022;8(15):1733–1742. doi:10.2147/IDR.S357300
  • Cattaneo D, Orlando G, Cozzi V, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents. 2013;41(6):586–589. doi:10.1016/j.ijantimicag.2013.02.020
  • Lee BJ, Vu BN, Seddon AN, Hodgson HA, Wang SK. Treatment considerations for CNS infections caused by vancomycin-resistant Enterococcus faecium: a focused review of linezolid and daptomycin. Ann Pharmacother. 2020;54(12):1243–1251. doi:10.1177/1060028020932513
  • Hu F, Zhu D, Wang F, Wang M. Current status and trends of antibacterial resistance in China. Clin Infect Dis. 2018;67(suppl_2):S128–S134. doi:10.1093/cid/ciy657
  • Wang J, Zhou M, Huang G, et al. Antimicrobial resistance in southern China: results of prospective surveillance in Dongguan city, 2017. J Hosp Infect. 2020;105(2):188–196. doi:10.1016/j.jhin.2020.03.029
  • Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect. 2019;25(8):943–950. doi:10.1016/j.cmi.2019.04.013
  • Bonomo RA, Burd EM, Conly J, et al. Carbapenemase-producing organisms: a global scourge. Clin Infect Dis. 2018;66(8):1290–1297. doi:10.1093/cid/cix893
  • Bassetti M, Peghin M, Pecori D. The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2016;29(6):583–594. doi:10.1097/QCO.0000000000000314
  • Han R, Shi Q, Wu S, et al.; China Antimicrobial Surveillance Network (CHINET) Study Group. Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China. Front Cell Infect Microbiol. 2020;10:314. doi:10.3389/fcimb.2020.00314
  • Lu MC, Chen YT, Tang HL, et al. Transmission and evolution of OXA-48-producing Klebsiella pneumoniae ST11 in a single hospital in Taiwan. J Antimicrob Chemother. 2020;75(2):318–326. doi:10.1093/jac/dkz431
  • Chen Y, Fang L, Yang Y, et al. Emergence of carbapenem-resistant Klebsiella pneumoniae harbouring bla OXA-48-like genes in China. J Med Microbiol. 2021;70(3):001306. doi:10.1099/jmm.0.001306
  • Yin D, Dong D, Li K, et al. Clonal dissemination of OXA-232 carbapenemase-producing Klebsiella pneumoniae in neonates. Antimicrob Agents Chemother. 2017;61(8):e00385–17. doi:10.1128/AAC.00385-17
  • Jenkins A, Thomson AH, Brown NM, et al.; (BSAC Working Party on Therapeutic Drug Monitoring). Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. J Antimicrob Chemother. 2016;71(10):2754–2759. doi:10.1093/jac/dkw250